ReviewExpert opinion on biological therapy2012
Current ebola vaccines.
Review in Expert opinion on biological therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 82 citations in OpenAlex.
- Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines.Antiviral research · 2024Article
- Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.Recent advances in anti-infective drug discovery · 2024Review
- A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines · 2022Review
- Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP.Frontiers in bioengineering and biotechnology · 2022Article
- Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review.BMJ open · 2019Article
- Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.Human vaccines & immunotherapeutics · 2019Review
- Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.Journal of virology · 2017Article
- Expression of an immunogenic LTB-based chimeric protein targeting Zaire ebolavirus epitopes from GP1 in plant cells.Plant cell reports · 2017Article
- A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus.Frontiers in immunology · 2017Review
- Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us.Microbiology spectrum · 2016Article
- Therapeutic potential of the heme oxygenase-1 inducer hemin against Ebola virus infection.Current trends in immunology · 2016Article
- Future Challenges for Vaccinologists.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Highly conserved regions in Ebola virus RNA dependent RNA polymerase may be act as a universal novel peptide vaccine target: a computational approach.In silico pharmacology · 2015Article
- Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Development of Small-Molecule Antivirals for Ebola.Medicinal research reviews · 2015Review
- Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.Molecular pharmaceutics · 2015Article
- Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study.Scandinavian journal of immunology · 2015Article
- Ebolavirus and Haemorrhagic Syndrome.Sultan Qaboos University medical journal · 2015Review
- Harnessing case isolation and ring vaccination to control Ebola.PLoS neglected tropical diseases · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionEbolaviruses cause severe viral hemorrhagic fever in humans and non-human primates (NHPs), with case fatality rates of up to 90%. Currently, neither a specific treatment nor a vaccine licensed for use in humans is available. However, a number of vaccine candidates have been developed in the last decade that are highly protective in NHPs, the gold standard animal model for ebola hemorrhagic fever. AREAS COVERED: This review analyzes a number of scenarios for the use of ebolavirus vaccines, discusses the requirements for ebolavirus vaccines in these scenarios and describes current ebolavirus vaccines. Among these vaccines are recombinant adenoviruses, recombinant vesicular stomatitis viruses (VSVs), recombinant human parainfluenza viruses and virus-like particles. Interestingly, one of these vaccine platforms, based on recombinant VSVs, has also demonstrated post-exposure protection in NHPs. EXPERT OPINION: The most pressing remaining challenge is now to move these vaccine candidates forward into human trials and toward licensure. In order to achieve this, it will be necessary to establish the mechanisms and correlates of protection for these vaccines, and to continue to demonstrate their safety, particularly in potentially immunocompromised populations. However, already now there is sufficient evidence that, from a scientific perspective, a vaccine protective against ebolaviruses is possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.